Hexamethylmelamine-A new drug with activity in solid tumors

Ronald H. Blum, Robert B. Livingston, Stephen K. Carter

Research output: Contribution to journalArticle

64 Scopus citations

Abstract

Hexamethylmelamine (NSC 13875) is a iriazine that has completed phase I-II trials under the sponsorship of the Division of Cancer Treatment, National Cancer Institute. It was selected for clinical trial based on superior activity against the Walker 256 carcinosarcoma. In the clinical trials reported, the dose schedules used were 4-15 mg/kd/d for 21-90 days. Dose limiting toxicity was gastrointestinal. Also seen were leukopenia, thrombocylopenia, and central nervous system toxicity. The overall response rate in 784 evaluable patients was 17%. Greater than 20% response rates were seen in the following tumor types: small cell (oat) carcinoma of the lung, ovarian adenocarcinoma, lymphoma, and breast cancer. Further controlled clinical trials in certain tumor types are warranted.

Original languageEnglish (US)
Pages (from-to)195-202
Number of pages8
JournalEuropean Journal of Cancer (1965)
Volume9
Issue number3
DOIs
StatePublished - Mar 1973

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this